Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Annales d'endocrinologie Pub Date : 2025-09-15 DOI:10.1016/j.ando.2025.101860

M. Alissou Dr , T. Demangeat Dr , V. Folope Dr , H. Van Elslande Dr , H. Lelandais Dr , J. Blanchemaison Dr , C. Pierre-Emmanuel Dr , S. Guney Dr , A. Aupetit Dr , A. Petit Dr , M. Godin Dr , L. Vignal Dr , S. Grigioni Dr , P. Dechelotte Pr , G. Colange Dr , M. Coëffier Pr , N. Achamrah Pr

{"title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study","authors":"M. Alissou Dr , T. Demangeat Dr , V. Folope Dr , H. Van Elslande Dr , H. Lelandais Dr , J. Blanchemaison Dr , C. Pierre-Emmanuel Dr , S. Guney Dr , A. Aupetit Dr , A. Petit Dr , M. Godin Dr , L. Vignal Dr , S. Grigioni Dr , P. Dechelotte Pr , G. Colange Dr , M. Coëffier Pr , N. Achamrah Pr","doi":"10.1016/j.ando.2025.101860","DOIUrl":null,"url":null,"abstract":"<div><div>Limited data exist on impact of semaglutide on lean mass and muscle function. The SEMALEAN study aims to evaluate these parameters in patients with obesity treated with Semaglutide (2.4mg).</div><div>This prospective study enrolled 115 patients with obesity between February 2022 and December 2023. Body weight, body composition (measured by DXA) and muscle function (handgrip strength) were assessed at baseline (M0), 7 months (M7), and 12 months (M12).</div><div>A total of 106 patients (68.9% female; mean BMI 46.3kg/m<sup>2</sup>) completed the study. Weight loss was significant, with mean reductions of 10% at M7 and 13% at M12; 59% of patients achieved ≥10% weight loss. Total fat mass decreased by 14% at M7 and 18% at M12, while lean mass initially declined (−3kg at M7) but stabilized thereafter. Handgrip strength improved significantly (+4.5kg at M12), and the prevalence of sarcopenic obesity decreased from 49% at baseline to 33% at M12. Subgroup analyses revealed greater weight and fat mass loss in women, while patients with type 2 diabetes or prior GLP-1 analog use showed attenuated responses. Patients with a history of bariatric surgery exhibited the most pronounced reductions in body composition parameters.</div><div>The SEMALEAN study highlights the significant impact of semaglutide 2.4mg on weight loss, fat mass reduction, and muscle function improvement, with preserved lean mass and metabolic efficiency. These findings underscore the importance of a comprehensive approach to obesity management, addressing not only weight loss but also functional and metabolic adaptation.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 6","pages":"Article 101860"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales d'endocrinologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003426625001799","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Limited data exist on impact of semaglutide on lean mass and muscle function. The SEMALEAN study aims to evaluate these parameters in patients with obesity treated with Semaglutide (2.4 mg).

This prospective study enrolled 115 patients with obesity between February 2022 and December 2023. Body weight, body composition (measured by DXA) and muscle function (handgrip strength) were assessed at baseline (M0), 7 months (M7), and 12 months (M12).

A total of 106 patients (68.9% female; mean BMI 46.3 kg/m²) completed the study. Weight loss was significant, with mean reductions of 10% at M7 and 13% at M12; 59% of patients achieved ≥10% weight loss. Total fat mass decreased by 14% at M7 and 18% at M12, while lean mass initially declined (−3 kg at M7) but stabilized thereafter. Handgrip strength improved significantly (+4.5 kg at M12), and the prevalence of sarcopenic obesity decreased from 49% at baseline to 33% at M12. Subgroup analyses revealed greater weight and fat mass loss in women, while patients with type 2 diabetes or prior GLP-1 analog use showed attenuated responses. Patients with a history of bariatric surgery exhibited the most pronounced reductions in body composition parameters.

The SEMALEAN study highlights the significant impact of semaglutide 2.4 mg on weight loss, fat mass reduction, and muscle function improvement, with preserved lean mass and metabolic efficiency. These findings underscore the importance of a comprehensive approach to obesity management, addressing not only weight loss but also functional and metabolic adaptation.

查看原文本刊更多论文

SEMALEAN研究：西马鲁肽对肥胖患者脂肪质量、瘦质量和肌肉功能的影响

关于西马鲁肽对瘦质量和肌肉功能影响的数据有限。SEMALEAN研究旨在评估接受Semaglutide （2.4 mg）治疗的肥胖患者的这些参数。这项前瞻性研究在2022年2月至2023年12月期间招募了115名肥胖患者。在基线（M0）、7个月（M7）和12个月（M12）时评估体重、身体组成（通过DXA测量）和肌肉功能（握力）。共有106例患者（68.9%为女性，平均BMI为46.3 kg/m2）完成了研究。体重减轻显著，在M7和M12时平均减少10%和13%；59%的患者体重减轻≥10%。总脂肪质量在M7和M12时分别下降14%和18%，而瘦肉质量在M7时开始下降（- 3 kg），但此后趋于稳定。握力显著提高（M12时增加4.5 kg），肌肉减少型肥胖的患病率从基线时的49%下降到M12时的33%。亚组分析显示，女性的体重和脂肪减少更大，而2型糖尿病患者或既往使用GLP-1类似物的患者则表现出减弱的反应。有减肥手术史的患者表现出最明显的身体成分参数下降。SEMALEAN研究强调了2.4 mg semaglutide对减肥、减少脂肪量和改善肌肉功能的显著影响，并保留了瘦质量和代谢效率。这些发现强调了肥胖管理综合方法的重要性，不仅要解决减肥问题，还要解决功能和代谢适应问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annales d'endocrinologie 医学-内分泌学与代谢

CiteScore

4.40

自引率

6.50%

发文量

311

审稿时长

50 days

期刊介绍： The Annales d''Endocrinologie, mouthpiece of the French Society of Endocrinology (SFE), publishes reviews, articles and case reports coming from clinical, therapeutic and fundamental research in endocrinology and metabolic diseases. Every year, it carries a position paper by a work-group of French-language endocrinologists, on an endocrine pathology chosen by the Society''s Scientific Committee. The journal is also the organ of the Society''s annual Congress, publishing a summary of the symposia, presentations and posters. "Les Must de l''Endocrinologie" is a special booklet brought out for the Congress, with summary articles that are always very well received. And finally, we publish the high-level instructional courses delivered during the Henri-Pierre Klotz International Endocrinology Days. The Annales is a window on the world, keeping alert clinicians up to date on what is going on in diagnosis and treatment in all the areas of our specialty.